Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Opko

Digital icon inside Cuttsy+Cuttsy branded shapes

Clinical trial considerations: Why digital matters…

Digital technology in healthcare is rapidly evolving. In this blog we delve into how digital solutions can help improve patient experience within clinical trials.

Cuttsy + Cuttsy

- PMLiVE

Pfizer/BioNTech’s COVID-19 vaccine available to buy in UK following MHRA endorsement

The XBB.1.5-adapted vaccine will be available for purchase from March 2024

Imagery icons in Cuttsy+Cuttsy branded shapes

Clinical trials explained: Why imagery matters…

Recruiting patients for clinical trials is one of pharma's greatest challenges. Imagery is a great way to connect with people on an emotional level and forms a big part the...

Cuttsy + Cuttsy

Health literacy icons in Cuttsy+Cuttsy branded shapes

Clinical trials explained: Why health literacy matters…

Clinical trial recruitment can be a challenge. By applying the principles of health literacy to all materials, we can support people to make an informed choice about whether to take...

Cuttsy + Cuttsy

- PMLiVE

New framework establishes two tests for use in clinical trials for Parkinson’s

The neurological condition currently affects around 145,000 people in the UK

- PMLiVE

Pfizer’s Talzenna recommended by NICE for advanced breast cancer

An estimated 300 patients will be eligible for treatment with the PARP inhibitor

icons related to iconography inside Cuttsy+Cuttsy branded shapes

Clinical trials explained: Why iconography matters…

Icons serve as a useful form of alternative communication. We spend a lot of time developing icons for healthcare communications. Find out how we use iconography to elevate clinical trial...

Cuttsy + Cuttsy

- PMLiVE

Pfizer’s COVID-19 antiviral Paxlovid recommended by NICE for expanded use

The latest guidance will mean an estimated 5.3 million people will be eligible to access Paxlovid

- PMLiVE

Pfizer’s Talzenna combination receives EC approval for metastatic prostate cancer

Approximately 470,000 new cases of prostate cancer were reported in Europe in 2020

- PMLiVE

Novo Nordisk announces two new research collaborations for cardiometabolic diseases

The research programmes will develop novel treatments for obesity and MASH

- PMLiVE

Novo Nordisk’s once-weekly IcoSema shows promise in phase 3a type 2 diabetes trial

IcoSema showed non-inferiority to daily insulin treatment in reducing blood glucose levels

On a journey to diverse, inclusive, and more efficient rare disease trials

Although orphan drugs represent a sizeable portion of new drug approvals, most rare diseases still lack effective treatment. Even more so than for other conditions, rare disease management contains large care...

Impetus Digital

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links